Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 103Lymphoma, Large B-Cell, Diffuse 32Neoplasms 23Lymphoma, Non-Hodgkin 20Lymphoma, Follicular 20Lymphoma 19Multiple Myeloma 15Lymphoma, B-Cell 11Neoplasm Metastasis 10Recurrence 8Lymphoma, T-Cell, Peripheral 7Prostatic Neoplasms, Castration-Resistant 5Prostate Cancer Metastatic 5Metastatic Castration-resistant Prostate Cancer 5Lymphoma, Mantle-Cell 5Hematologic Diseases 5Lymphoma, B-Cell, Marginal Zone 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Metastatic Castration-Resistant Prostate Cancer 3Leukemia, Lymphocytic, Chronic, B-Cell 3Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Pain 2Metastatic Castration Resistant Prostate Cancer 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphatic Diseases 2Leukemia 2Graft vs Host Disease 2

Interventions

enzalutamide 8Abiraterone Acetate 4rucaparib 2Prednisone 2Docetaxel 2sabizabulin 1fluzoparib 1apatinib 1abiraterone 1Pluvicto 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Metastatic Castration Resistant Prostate Cancer × Prednisone × Clear all
NCT04869488 2025-01-24

A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
93 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT04056754 2019-08-14

Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Completed
268 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡